
## Jan Ã-stergren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/323536/publications.pdf Version: 2024-02-01



IAN Ã-STEDODEN

#	Article	IF	CITATIONS
1	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, The, 2003, 361, 1149-1158.	13.7	3,420
2	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, The, 2005, 366, 895-906.	13.7	2,662
3	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.	13.7	2,584
4	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, The, 2003, 362, 767-771.	13.7	1,978
5	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	13.7	1,752
6	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, The, 2003, 362, 772-776.	13.7	1,623
7	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	2.2	1,144
8	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
9	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 1377-1385.	2.2	549
10	Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, The, 2005, 366, 907-913.	13.7	314
11	Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. Journal of the American College of Cardiology, 2007, 49, 687-694.	2.8	268
12	Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Journal of Cardiac Failure, 1999, 5, 276-282.	1.7	260
13	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. Circulation, 2007, 115, 3111-3120.	1.6	235
14	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 986-994.	1.6	229
15	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <scp>CHARM</scp> â€Preserved. European Journal of Heart Failure, 2014, 16, 33-40.	7.1	186
16	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 2641-2650.	2.2	164
17	Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal, 2006, 27, 2982-2988.	2.2	146
18	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2011, 162, 900-906.	2.7	143

Jan Ã-stergren

#	Article	IF	CITATIONS
19	factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clinical Cardiology, 2001, 24, 238-244.	1.8	122
20	Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiologica Scandinavica, 1984, 121, 165-171.	2.2	110
21	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial. American Heart Journal, 2006, 151, 985-991.	2.7	102
22	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. Journal of Hypertension, 2008, 26, 2103-2111.	0.5	98
23	The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal, 2008, 29, 499-508.	2.2	83
24	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2005, 294, 1794.	7.4	66
25	Evaluation of a web-based ECC-interpretation programme for undergraduate medical students. BMC Medical Education, 2008, 8, 25.	2.4	61
26	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 2009, 32, 915-920.	8.6	61
27	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 2010, 12, 557-565.	7.1	59
28	Associations Between Crowding and Ten-Day Mortality Among Patients Allocated Lower Triage Acuity Levels Without Need of Acute Hospital Care on Departure From the Emergency Department. Annals of Emergency Medicine, 2019, 74, 345-356.	0.6	51
29	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Pressure, 2008, 17, 7-17.	1.5	49
30	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. European Journal of Heart Failure, 2007, 9, 510-517.	7.1	47
31	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 2008, 52, 2000-2007.	2.8	42
32	Physicians' and nurses' perceptions of patient safety risks in the emergency department. International Emergency Nursing, 2017, 33, 14-19.	1.5	42
33	Contributing factors to errors in Swedish emergency departments. International Emergency Nursing, 2015, 23, 156-161.	1.5	36
34	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2005, 27, 1447-1458.	2.2	35
35	High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm. Blood Pressure, 2018, 27, 249-255.	1.5	34
36	Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 64-73.	1.7	33

Jan Ã-stergren

#	Article	IF	CITATIONS
37	Renin–angiotensin-system blockade in the prevention of diabetes. Diabetes Research and Clinical Practice, 2007, 76, S13-S21.	2.8	28
38	Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Annals of Medicine, 2012, 44, 262-270.	3.8	26
39	Does individual learning styles influence the choice to use a web-based ECG learning programme in a blended learning setting?. BMC Medical Education, 2012, 12, 5.	2.4	25
40	Skin capillary blood cell velocity in patients with arterial obliterative disease and polycythaemia: a disturbed reactive hyperaemia response. Clinical Physiology, 1985, 5, 35-43.	0.7	24
41	Regression of Left Ventricular Mass with Captopril and Metoprolol, and the Effects on Glucose and Lipid Metabolism. Blood Pressure, 2001, 10, 101-110.	1.5	24
42	Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 75-81.	2.8	24
43	Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. American Journal of Cardiology, 1999, 84, 104-108.	1.6	20
44	Plasma NTâ€proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Pressure, 2005, 14, 99-106.	1.5	20
45	Comparison of CNSâ€Related Subjective Symptoms in Hypertensive Patients Treated with Either a New Controlled Release (CR/ZOK) Formulation of Metoprolol or Atenolol. Journal of Clinical Pharmacology, 1990, 30, S82-90.	2.0	19
46	Videophotometric capillaroscopy for evaluating drug effects on skin microcirculation—a doubleâ€blind study with nifedipine. Clinical Physiology, 1984, 4, 169-176.	0.7	17
47	Factors influencing clinicians' perceptions of interruptions as disturbing or non-disturbing: A qualitative study. International Emergency Nursing, 2016, 27, 11-16.	1.5	17
48	Effect of Amlodipine Versus Felodipine Extended Release on 24-Hour Ambulatory Blood Pressure in Hypertension. American Journal of Hypertension, 1998, 11, 690-696.	2.0	14
49	Candesartan for the treatment of hypertension and heart failure. Expert Opinion on Pharmacotherapy, 2004, 5, 1589-1597.	1.8	14
50	Skin microvascular dilatation response to acetylcholine and sodium nitroprusside in peripheral arterial disease. Clinical Physiology and Functional Imaging, 2002, 22, 370-374.	1.2	13
51	Where Are We With the Management of Hypertension? From Science to Clinical Practice. Journal of Clinical Hypertension, 2009, 11, 66-73.	2.0	13
52	Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein but Not Cystatin C Predict Cardiovascular Events in Male Patients with Peripheral Artery Disease Independently of Ambulatory Pulse Pressure. American Journal of Hypertension, 2014, 27, 363-371.	2.0	13
53	Acrodermatitis Chronica Atrophicans Herxheimer Can Often Mimic a Peripheral Vascular Disorder. Acta Medica Scandinavica, 2009, 220, 485-488.	0.0	12
54	Significant changes in emergency department length of stay and case mix over eight years at a large Swedish University Hospital. International Emergency Nursing, 2019, 43, 50-55.	1.5	11

Jan Östergren

#	Article	IF	CITATIONS
55	Reasons for interrupting colleagues during emergency department work – A qualitative study. International Emergency Nursing, 2016, 29, 21-26.	1.5	9
56	Ambulatory pulse pressure predicts cardiovascular events in patients with peripheral arterial disease. Blood Pressure, 2012, 21, 227-232.	1.5	8
57	Systolic blood pressure increases in patients with atrial fibrillation regaining sinus rhythm after electrical cardioversion. Journal of Clinical Hypertension, 2019, 21, 363-368.	2.0	8
58	Angiotensin receptor blockers in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 171-175.	1.7	5
59	Change in blood pressure during hospitalisation for acute heart failure predicts mortality. Scandinavian Cardiovascular Journal, 2010, 44, 325-330.	1.2	5
60	Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure, 2012, 21, 82-87.	1.5	4
61	Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. Journal of Clinical Hypertension, 2015, 17, 141-146.	2.0	4
62	Corrigendum to â€~Analysing recurrent hospitalizations in heart failure: a review ofÂstatistical methodology, with application toÂCHARM-Preserved' [Eur J Heart Fail2014;16:33-40]. European Journal of Heart Failure, 2014, 16, 592-592.	7.1	3
63	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease—A randomized controlled trial. International Journal of Cardiology: Hypertension, 2021, 8, 100074.	2.2	3
64	Adrenaline Responsiveness in Mild Hypertension: No Evidence for Altered β-Adrenoceptor Sensitivity. Journal of Cardiovascular Pharmacology, 1998, 32, 753-759.	1.9	3
65	Why Medical Students Choose to Use or Not to Use a Web-Based Electrocardiogram Learning Resource: Mixed Methods Study. JMIR Medical Education, 2019, 5, e12791.	2.6	3
66	Changes in 24-h ambulatory blood pressure following restoration of sinus rhythm in patients with atrial fibrillation. Journal of Hypertension, 2021, 39, 243-249.	0.5	3
67	Myocardial ischaemia in patients with peripheral arterial disease. Clinical Physiology and Functional Imaging, 2007, 27, 30-35.	1.2	1
68	Improvement of blood pressure control and physicians' management over time in patients with coronary artery disease. Blood Pressure, 2016, 25, 286-291.	1.5	1
69	Urokinase reduced the need for open surgical procedures in acute ischemia of the leg. Evidence-based Cardiovascular Medicine, 1998, 2, 82.	0.0	0